Sudeep Pharma’s Rs 895-crore IPO enters its final bidding day with strong overall demand, led by robust NII and retail participation. Despite a softening grey-market premium, subscription momentum remains healthy. Backed by diversified excipient capabilities, steady financial growth and anchor interest, the company is positioned favourably as it approaches allotment and listing. Source link India After Saudi Arabia sent Pakistanis… Rohit Pawar seeks probe into … Kerala MLA Rahul Mamkootathil… Cyclone Ditwah LIVE: Intense… Stock Market Retire in the Southwest in These 5… Asia in the AI Money Machine Psychologists say this 'green… Ashoka Buildcon shares slip 6% in……